GlobalData on MSN

Abbott reports positive FREEDM2 study results for CGM

The study was carried out at 24 clinical sites across the UK and included 303 participants.
Drug Delivery Business

Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin

Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).

What you should know about wearable glucose monitors in wake of recall

About 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors manufactured by Abbott were recalled in November, because they might give wrong readings.
CNBC

FDA approves two new Abbott over-the-counter continuous glucose monitors

Abbott on Monday announced it has received FDA clearance for two new CGMs that will be available without a prescription. A CGM is a small sensor that pokes through the skin and tracks a person's ...
Hosted on MSN

Abbott’s studies show CGM technology linked to lower heart hospitalisation risk

Abbott's REFLECT real-world retrospective studies indicate that FreeStyle Libre continuous glucose monitoring (CGM) technology use is linked to a significant decrease in hospitalisation risk for heart ...
Medscape

Newer Abbott Libre CGM Sensor Use Now Okay During Imaging

The US Food and Drug Administration (FDA) has cleared the Abbott Libre 2 and 3 continuous glucose monitoring (CGM) sensors for use during most imaging procedures, including MRI under certain ...
The American Journal of Managed Care

Abbott, Omada Health to Combine Digital Coaching With CGM for Those With Type 2 Diabetes

Omada Health, a longtime leader in digital health coaching for diabetes prevention and type 2 diabetes (T2D) care, and Abbott, maker of the FreeStyle Libre, said the partnership will “create a new ...